J
John C. Burnett
Researcher at Beckman Research Institute
Publications - 54
Citations - 4292
John C. Burnett is an academic researcher from Beckman Research Institute. The author has contributed to research in topics: Systematic evolution of ligands by exponential enrichment & Aptamer. The author has an hindex of 25, co-authored 52 publications receiving 3880 citations. Previous affiliations of John C. Burnett include University of California, Berkeley & City of Hope National Medical Center.
Papers
More filters
Journal ArticleDOI
RNA-based therapeutics: current progress and future prospects.
John C. Burnett,John J. Rossi +1 more
TL;DR: Promising results from recent clinical trials suggest that barriers to clinical progress of RNA-based drugs may be overcome with improved synthetic delivery carriers and chemical modifications of the RNA therapeutics.
Journal ArticleDOI
Stochastic Gene Expression in a Lentiviral Positive-Feedback Loop: HIV-1 Tat Fluctuations Drive Phenotypic Diversity
Leor S. Weinberger,John C. Burnett,John C. Burnett,Jared E. Toettcher,Adam P. Arkin,Adam P. Arkin,David V. Schaffer,David V. Schaffer +7 more
TL;DR: In this article, the authors present an extensive experimental/computational study of an HIV-1 model vector (LTR-GFP-IRES-Tat) and show that stochastic fluctuations in Tat influence the viral latency decision.
Posted Content
Stochastic Gene Expression in a Lentiviral Positive Feedback Loop: HIV-1 Tat Fluctuations Drive Phenotypic Diversity
Leor S. Weinberger,John C. Burnett,John C. Burnett,Jared E. Toettcher,Adam P. Arkin,Adam P. Arkin,David V. Schaffer,David V. Schaffer +7 more
TL;DR: Stochastic computational modeling successfully accounted for PheB and correctly predicted the dynamics of a Tat mutant that were subsequently confirmed by experiment, illustrating the importance of stochastic fluctuations in gene expression in a mammalian system.
Journal ArticleDOI
Current progress of siRNA/shRNA therapeutics in clinical trials
TL;DR: An overview of siRNA therapeutics in clinical trials is provided, including their clinical progress, the challenges they have encountered, and the future they hold in the treatment of human diseases.
Journal ArticleDOI
Circulating Natriuretic Peptide Concentrations in Patients With End-Stage Renal Disease: Role of Brain Natriuretic Peptide as a Biomarker for Ventricular Remodeling
Alessandro Cataliotti,Lorenzo Malatino,Michihisa Jougasaki,Carmine Zoccali,Pietro Castellino,Giuseppe Giacone,Ignazio Bellanuova,Rocco Tripepi,Giuseppe Seminara,Saverio Parlongo,Benedetta Stancanelli,G. Bonanno,Pasquale Fatuzzo,Francesco Rapisarda,Paola Belluardo,Salvatore Santo Signorelli,Denise M. Heublein,John G. Lainchbury,Hanna Leskinen,Kent R. Bailey,Margaret M. Redfield,John C. Burnett +21 more
TL;DR: Elevation of the plasma BNP concentration is more specifically related to LVH compared with the other NP levels in patients with ESRD independent of congestive heart failure, and serves as an important plasma biomarker for ventricular hypertrophy in dialysis patients withESRD.